Neurocrine Biosciences spent 2026 talking about concrete moves such as a US$2.9b cash deal for Soleno Therapeutics and fresh data readouts for CRENESSITY and VYKAT XR. Yet what really grabs attention ...
Source LinkNeurocrine Biosciences spent 2026 talking about concrete moves such as a US$2.9b cash deal for Soleno Therapeutics and fresh data readouts for CRENESSITY and VYKAT XR. Yet what really grabs attention ...
Source Link
Comments